Perez-Mateo M, Erill S
Int J Clin Pharmacol Biopharm. 1979 Apr;17(4):168-70.
The plasma protein binding of salicylate, a representative acidic drug, and of quinidine, a representative basic drug, has been studied in patients with multiple myeloma, a disease characterized by a profound alteration of the plasma protein pattern. Abnormal binding of salicylate was detected only in patients with high values of circulating abnormal protein. Plasma protein binding of quinidine was not altered in any of the patients studied.
已对患有多发性骨髓瘤(一种以血浆蛋白模式发生深刻改变为特征的疾病)的患者,研究了代表性酸性药物水杨酸盐以及代表性碱性药物奎尼丁的血浆蛋白结合情况。仅在循环异常蛋白值高的患者中检测到水杨酸盐的异常结合。在所研究的任何患者中,奎尼丁的血浆蛋白结合均未改变。